1404166-77-3

Upstream product

• 882974-64-3 6-{[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]methyl}-2,3-dihydropyridazin-3-one 
• 882974-16-5 6-[2-(4-fluorophenyl)-2-oxoethyl]-2,3-dihydropyridazin-3-one 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 882974-10-9 2-(6-chloropyridazin-3-yl)-1-(4-fluorophenyl)ethan-1-one 
• 1404166-69-3 (R)-6-(5-{[3-(benzyloxy)-2-(hydroxymethyl)propyl]-amino}-3-(4-fluorophenyl)-1H-pyrazol-4-yl)-2-(2-tolyl)-2,3-dihydropyridazin-3-one 
• 1404169-37-4 (R)-4-[3-(benzyloxy)-2-(hydroxymethyl)propyl]thiosemicarbazide 
• 124-63-0 methanesulfonyl chloride 
• 121-44-8 triethylamine 
• 1394849-30-9 (R)-3-amino-2-[(benzyloxy)methyl]propan-1-ol monohydrochloride 
• 1121-79-5 3-chloro-6-methylpyridazine 
• 882974-29-0 (RS)-6-[1-bromo-2-(4-fluorophenyl)-2-oxoethyl]-2-(2-tolyl)-2,3-dihydropyridazin-3-one 
• 882974-67-6 6-[2-(4-fluorophenyl)-2-oxoethyl]-2-(2-tolyl)-2,3-dihydropyridazin-3-one 
• 882974-45-0 6-{[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]methyl}-2-(2-tolyl)-2,3-dihydropyridazin-3-one 

Downstream Products

• 928344-12-1 A⁽⁴⁰⁴⁾S₁₉₇₇ 

Relevant academic research and scientific papers

Development of a practical and scalable synthesis of a potent p38 mitogen-activated protein kinase inhibitor

Process research and development of a practical and scalable synthetic method toward a potent inhibitor of p38 mitogen-activated protein kinase 1 is described. The medicinal chemistry synthetic method had several issues in scale-up synthesis. In contrast, the synthetic method described here does not require purification by column chromatography for all steps, and the formation of impurities is suppressed well. Aminopyrazole ring formation was achieved by reaction between a new chiral amine building block 7 and bromoketone unit 4 as a key reaction. This highly efficient and scalable process was successfully demonstrated in the large-scale synthesis of 1·HBr.